Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lunsayil LTE: Long-term Spesolimab in Hidradenitis Suppurativa
NCT06241573Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 2024
- Primary completion
- Apr 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of spesolimab in hidradenitis suppurativa (HS), sponsored by Boehringer Ingelheim. Started May 2024; status: terminated.
02
Drugs
spesolimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06241573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06241573.